Mechanism of action, homeostatic role and therapeutic effects of CD52

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1051484

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

T cells are required to fight infections but sometimes attack our tissues and cause autoimmune disease. T cells called regulatory T (Treg) cells suppress other T cells that cause autoimmune disease. We discovered a new type of Treg cell that suppresses other T cells by releasing from its surface a protein called CD52. We aim to discover how CD52 works and show that it can prevent autoimmune disease. We will gain insight into how the immune system regulates itself and may identify a new drug for the treatment of autoimmune diseases.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2015

Funding Scheme: Project Grants

Funding Amount: $410,902.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

T cell immunotherapy | T cell receptor | T cells | autoimmune disease | type 1 diabetes mellitus (insulin-dependent diabetes mellitus)

Related Links